A new link between two proteins tied to Parkinson’s has implications for the disease and beyond.
The most detailed connectivity map for the mammalian brain to date will allow investigators to track neuronal networks at an unprecedented scale.
Hardening of the arteries correlated with greater amyloid deposition in a longitudinal study, strengthening ties between cardiovascular disease and Alzheimer’s.
When a calcium sensor disappears from dendritic spines, synapse loss soon follows in Alzheimer’s models, aging mice, and diseased human brains.
IMAGINE that: Amyloid deposition shrinks in both treatment and placebo groups, dealing a blow to the anti-aggregation drug PBT2.
Astrocytes kindle neuronal hyperexcitability in mouse models of Huntington’s.
An antioxidant thought to boost mitochondrial function came up short in a large multicenter trial for PD treatment.
PINK1 mutations cripple mitochondrial energy production, raising new questions about Parkinson’s disease.
Keystone presenters pulled out new tools to make connections between genetics and disease.
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
A Keystone symposium underscores the role of lysosomal dysfunction and vesicle trafficking in neurodegenerative disease.
The 2014 Alzheimer’s Association report finds that women bear the brunt of AD, being more likely to develop the disease or care for someone with AD full time.
Combination therapies may work where single drugs fall short, but testing them in AD may prove challenging.
Network analysis may explain why people with semantic dementia keep making memories even as their hippocampi degenerate.